Navigation Links
W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Date:4/7/2008

AURORA, ON, April 7 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)

Helix BioPharma Corp. today announced that the board of directors has increased the authorized number of directors from six to seven and has appointed Mr. W. Thomas Hodgson as director to fill the newly created position. Mr. Hodgson will also serve as chair of the three member Audit Committee, replacing Mr. Jack Kay who previously held the position.

Mr. Hodgson is currently senior partner and chairman of Greenbrook Capital Partners and acts as an advisor to the chairman of Magna Entertainment Corp. Mr. Hodgson's prior roles include senior positions with Canadian financial institutions and U.K. based companies.

Donald Segal, chief executive officer of Helix BioPharma, said, "Tom's diverse professional background and capital markets experience will be an invaluable resource to the board. In addition, his extensive knowledge of complex financial matters makes him ideally suited to chair our audit committee. We look forward to his contributions."

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the content of this News

Release.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists
2. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
3. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
4. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
5. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
6. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
7. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
8. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
10. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... 19, 2017 , ... EDETEK, Inc., a clinical technology company ... launching two new additions of its award-winning cloud-based platform CONFORM™: Information Hub and ... 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical trials ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... and commercialization, has just announced two more sessions of its “From the Helm” ... focus on the world of online templates for design control exercises. Led by ...
(Date:6/15/2017)... ... June 15, 2017 , ... New resistant soybean ... options for managing Palmer amaranth and other broadleaf weeds resistant to glyphosate. But ... necessary. Auxin herbicides are known to drift and to cause harm to sensitive, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):